// App-Quantinova.ai

2302 : DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Researchers

Presenter

  • Suzanne Trudel

Principal Investigators

  • Randy Davis

  • Nicole M. Lewis

  • Kalpana K. Bakshi

  • Bikramjit Chopra

  • Rocio Montes de Oca

  • Geraldine Ferron-Brady

  • Laurie Eliason

  • Brandon E. Kremer

  • Ira Gupta

  • Frank S. Wu

Medical Centers

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Biostatistics, GlaxoSmithKline, Research Triangle Park, NC

  • Clinical Development, GlaxoSmithKline, Upper Providence, PA

  • Pharmacovigilance, GlaxoSmithKline, London, United Kingdom

  • Experimental Medicine Unit Oncology, GlaxoSmithKline, Philadelphia, PA

  • Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Upper Providence, PA

  • Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA

  • Clinical Development, GlaxoSmithKline, Upper Providence, PA

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • GSK2857916

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Bortezomib

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multiple Arm

  • Multinational

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03715478

  • NCT04484623

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved